Drug Trial Radar · NCT07429474
Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Dec 15, 2026
Study completion Dec 15, 2026
Sponsor
- Lead sponsor
- Laboratorios Sophia S.A de C.V.Industry
- Sponsor type
- Industry
- First posted
- Feb 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I, prospective, interventional, open-label, multicenter clinical trial to evaluate the safety of intravitreal PRO-169 through the presence of serum anti-drug antibodies (ADAs) to bevacizumab.
Conditions
- Immunogenicity
- Anti-drug Antibodies (ADAs)
Interventions
PRO-169Biological
Bevacizumab 1.25 mg / 0.05mL for intravitreal injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with positive serum ADAs for bevacizumab.Time frame: Day 0 (Selection), day 30± 5 (visit 5, V5), day 60 ± 5 (visit 6, V6) and day 90± 5 (final visit, FV)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asociación para Evitar la Ceguera en México I.A.P
Coyoacán, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.